JP2017509335A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509335A5
JP2017509335A5 JP2016555472A JP2016555472A JP2017509335A5 JP 2017509335 A5 JP2017509335 A5 JP 2017509335A5 JP 2016555472 A JP2016555472 A JP 2016555472A JP 2016555472 A JP2016555472 A JP 2016555472A JP 2017509335 A5 JP2017509335 A5 JP 2017509335A5
Authority
JP
Japan
Prior art keywords
fusion protein
residue
multimeric fusion
region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509335A (ja
JP6851199B2 (ja
Filing date
Publication date
Priority claimed from GB201403914A external-priority patent/GB201403914D0/en
Priority claimed from GB201403915A external-priority patent/GB201403915D0/en
Priority claimed from GBGB1405955.4A external-priority patent/GB201405955D0/en
Priority claimed from GB201412648A external-priority patent/GB201412648D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/054688 external-priority patent/WO2015132365A1/en
Publication of JP2017509335A publication Critical patent/JP2017509335A/ja
Publication of JP2017509335A5 publication Critical patent/JP2017509335A5/ja
Application granted granted Critical
Publication of JP6851199B2 publication Critical patent/JP6851199B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555472A 2014-03-05 2015-03-05 多量体Fcタンパク質 Expired - Fee Related JP6851199B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1403915.0 2014-03-05
GB1403914.3 2014-03-05
GB201403914A GB201403914D0 (en) 2014-03-05 2014-03-05 Proteins
GB201403915A GB201403915D0 (en) 2014-03-05 2014-03-05 Proteins
GBGB1405955.4A GB201405955D0 (en) 2014-04-02 2014-04-02 Proteins
GB1405955.4 2014-04-02
GB201412648A GB201412648D0 (en) 2014-07-16 2014-07-16 Proteins
GB1412648.6 2014-07-16
PCT/EP2015/054688 WO2015132365A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (3)

Publication Number Publication Date
JP2017509335A JP2017509335A (ja) 2017-04-06
JP2017509335A5 true JP2017509335A5 (enExample) 2018-04-12
JP6851199B2 JP6851199B2 (ja) 2021-03-31

Family

ID=52697365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555472A Expired - Fee Related JP6851199B2 (ja) 2014-03-05 2015-03-05 多量体Fcタンパク質

Country Status (13)

Country Link
US (1) US20170081406A1 (enExample)
EP (1) EP3114137A1 (enExample)
JP (1) JP6851199B2 (enExample)
KR (1) KR20160127821A (enExample)
CN (1) CN106132994A (enExample)
AU (1) AU2015226101B2 (enExample)
BR (1) BR112016020377A2 (enExample)
CA (1) CA2939201A1 (enExample)
IL (1) IL247246A0 (enExample)
MX (1) MX2016010953A (enExample)
RU (1) RU2016139022A (enExample)
SG (1) SG11201606596PA (enExample)
WO (1) WO2015132365A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
CN113501880A (zh) 2014-05-02 2021-10-15 动量制药公司 涉及工程化Fc构建体的组合物和方法
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
HUE053062T2 (hu) 2015-07-24 2021-06-28 Gliknik Inc Humán fehérjefragmensek fúziós fehérjéi szabályosan multimerizált, fokozott komplementkötésû immunglobulin FC kompozíciók elõállításához
US20190119377A1 (en) * 2016-01-27 2019-04-25 Csl Behring Recombinant Facility Ag Recombinant igg fc multimers
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
AU2017272111B2 (en) 2016-05-23 2024-05-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
US20190389941A1 (en) 2016-07-22 2019-12-26 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
SG10202107391YA (en) 2017-01-06 2021-08-30 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CN113603781B (zh) * 2017-03-28 2022-09-02 礼进生物医药科技(上海)有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
CN112004550A (zh) * 2017-12-14 2020-11-27 康诺贝林伦瑙有限公司 用于治疗视神经脊髓炎的重组IgG Fc多聚体
US12492231B2 (en) 2018-11-14 2025-12-09 Jn Biosciences Llc Multimeric hybrid Fc proteins for replacement of IVIG
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP4028415A1 (en) 2019-09-13 2022-07-20 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders
CN114786721B (zh) * 2019-12-06 2025-10-17 康诺贝林伦瑙有限公司 Fc多聚体的稳定组合物
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业(上海)股份有限公司 一种cdc平台抗体
CN117925664B (zh) * 2023-11-29 2025-01-21 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2250279E (pt) * 2008-02-08 2016-06-03 Medimmune Llc Anticorpos anti-ifnár1 com afinidade reduzida para o ligando fc
AU2009224690B2 (en) * 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
EP2389192A4 (en) * 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
US9540442B2 (en) * 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Similar Documents

Publication Publication Date Title
JP2017509335A5 (enExample)
JP2017512063A5 (enExample)
JP2018502572A5 (enExample)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
JP2016526909A5 (enExample)
RU2016139006A (ru) Мультимерные fc-белки
JP2019516665A5 (enExample)
JP2021020905A5 (enExample)
JP2019522465A5 (enExample)
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2020500015A5 (enExample)
JP2014506790A5 (enExample)
JP2005120106A5 (enExample)
FI3998285T3 (fi) Cd38:aan ja pd-l1:een sitoutuvia molekyylejä
RU2013140685A (ru) ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2020529841A5 (enExample)
JP2019512222A5 (enExample)
IL309260B1 (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
FI2968461T3 (fi) Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi
MX2009012319A (es) Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
JP2015146822A5 (enExample)
JP2016525100A5 (enExample)